Literature DB >> 27566019

Low CDX1 expression predicts a poor prognosis for hepatocellular carcinoma patients after hepatectomy.

Hao Zheng1, Yuan Yang1, Meng-Chao Wang1, Sheng-Xian Yuan1, Tao Tian1, Jun Han1, Jun-Sheng Ni1, Jian Wang1, Hao Xing1, Wei-Ping Zhou2.   

Abstract

The caudal-type homeobox 1 (CDX1) transcription factor is a member of the caudal-related homeobox transcription factor gene family and has been reported to be down-regulated in a variety of cancers. However, the expression status and significance of CDX1 in hepatocellular carcinoma (HCC) is still controversial, and little is known about the role of CDX1 in HCC·In our previous study, we investigated the expression and clinical significance of CDX1 in HCC samples from 313 HCC patients. We found CDX1 was strikingly down-regulated in HCC samples. CDX1 expression was associated with poor differentiation (P = 0.002), and patients with low CDX1 expression had a significantly poorer prognosis. A subgroup analysis revealed a difference in prognosis between groups with low and high CDX1 expression among patients who had tumors <5 cm in size and who were alpha-fetoprotein (AFP) negative. Moreover, low expression was more frequently observed in the early recurrence group (within 2 years, P = 0.002). In addition, multivariate Cox regression analysis indicated that the CDX1 expression level, tumor size, presence of hepatitis B e antigen (HBeAg), vascular invasion, and presence of hepatitis B surface antigen (HBsAg) were independent risk factors for HCC recurrence, and the CDX1 expression level, tumor size, tumor number, and presence of HBsAg were independent predictor of overall survival of HCC patients. In conclusion, the downregulation of CDX1 is associated with poor prognosis; and it may serve as a novel predictor of the prognosis of HCC patients after curative resection.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CDX1; Clinical significance; Differentiation; Hepatocellular carcinomas; Immunohistochemistry

Mesh:

Substances:

Year:  2016        PMID: 27566019     DOI: 10.1016/j.suronc.2016.05.026

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  4 in total

1.  SKA3 Promotes Cell Growth in Breast Cancer by Inhibiting PLK-1 Protein Degradation.

Authors:  Li-Wei Ruan; Peng-Peng Li; Lang-Ping Jin
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

Review 2.  Homeobox Genes and Hepatocellular Carcinoma.

Authors:  Kwei-Yan Liu; Li-Ting Wang; Shih-Hsien Hsu; Shen-Nien Wang
Journal:  Cancers (Basel)       Date:  2019-05-03       Impact factor: 6.639

3.  Prognosis and modulation mechanisms of COMMD6 in human tumours based on expression profiling and comprehensive bioinformatics analysis.

Authors:  Mi Yang; Weiqiang Huang; Yaling Sun; Huazhen Liang; Min Chen; Xixi Wu; Xiaoqing Wang; Longshan Zhang; Xiaoya Cheng; Yao Fan; Hua Pan; Longhua Chen; Jian Guan
Journal:  Br J Cancer       Date:  2019-09-16       Impact factor: 7.640

4.  Primary mesenchymal chondrosarcoma of the kidney without HEY1-NCOA2 and IRF2BP2-CDX1 fusion: A case report and review.

Authors:  Atsushi Yamagishi; Osamu Ichiyanagi; Sei Naito; Hiromi Ito; Takanobu Kabasawa; Mitsunori Yamakawa; Norihiko Tsuchiya
Journal:  Oncol Lett       Date:  2019-11-22       Impact factor: 2.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.